Kalaris Therapeutics Inc To Discuss Initial Phase 1a Data Transcript
Greetings and welcome to Kalaris's phase 1A data disclosure conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and the number 0 on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Andrew Oxtoby, Chief Executive Officer.
Thank you, and you may begin.
Thank you, operator, and good afternoon, everyone.
As you likely saw, Kalaris issued a press release today announcing initial data from our phase 1A trial evaluating TH 103 in patients with neovascular, age-related macular degeneration. I'd like to remind everyone that this discussion and the accompanying presentation will contain forward-looking statements that are subject to the safe harbor protections provided under the Private Securities Litigation Reform
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
